Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1
Authors
Katherine Nedrow
Brenda Homony
Sharon L. Hillier
Sharon A. Riddler (ORCID: https://orcid.org/0000-0002-2545-7037)
Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1
Katherine Nedrow, Brenda Homony, Sharon L. Hillier, Sharon A. Riddler et al.
Citations
4 citations
Journal
The Journal of Infectious Diseases
Topics
HIV/AIDS drug development and treatment
Field-Weighted Citation Impact (FWCI)
5.58
article
Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1
Katherine Nedrow, Brenda Homony, Sharon L. Hillier, Sharon A. Riddler, Gonasagrie Nair, Keith D. Kaufman, Sharlaa Badal‐Faesen, Valerie Teal, Ciaran J. McMullan, Linda‐Gail Bekker, Craig W. Hendrix, Johannes Lombaard, Peggy Hwang, Rebeca M. Plank, Barbara J. Evans, Prachi Wickremasingha, Ryan C. Vargo, Yunping Zhou, Munjal Patel, Yoseph Caraco, M Robertson, P. Macdonald, Avivit Peer
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
The Journal of Infectious DiseasesVol. 232(5)
Institutions
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Desmond Tutu HIV Foundation (ZA), University of Cape Town (ZA), University of Pittsburgh (US), University of the Witwatersrand (ZA), Hadassah Medical Center (IL), Rambam Health Care Campus (IL), Magee-Womens Research Institute (US), Clinvet (ZA), Perinatal HIV Research Unit (ZA), Johns Hopkins Hospital (US)